Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Luspatercept in Lower Risk Myelodysplastic Syndromes
NCT06113302Phase 2Active, not recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Mar 2024
- Primary completion
- Jun 2028
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of luspatercept in myelodysplastic syndrome (MDS), sponsored by University of Texas MD Anderson Cancer Center. Started Mar 2024; status: active, not recruiting.
02
Drugs
luspatercept
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT06113302.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06113302.